Design of the vaccine and the expression of tumor antigen in target cells.

<p>(a): Design of the DNA-based replicon anti-tumor vaccine PSVK-shFcG-GM/B7.1. (b): Schematic representation of expression vectors. The shFcG-GM/B7.1 fusion gene, the shFcG fusion gene, and the GM/B7.1 fusion gene with a signal sequence were cloned into the PSVK vector under the control of the CMV promoter. ▪indicates signal sequences. (c): Expression of survivin and hCGβ in target tumor cells (B16F10-SUR and B16F10-hCGβ). Murine B16F10 cells were transfected with recombinant vectors containing pIRES-neo-SUR, pIRES-neo-hCGβ or the control vector.